Domain Therapeutics SA announced today that Domain Therapeutics grants Prexton Therapeutics an exclusive option to license and develop metabotropic glutamate receptor 4 (mGluR4) Positive Allosteric Modulator (PAM) drugs targeting ...
Tags: Domain Therapeutics SA, chemical, drugs